If at First You Don't Succeed, Spin It Off

Eli Lilly (NYSE: LLY  ) has apparently had enough of Xigris and its languishing sales --  just $57.3 million in U.S. revenue last year The drugmaker announced yesterday that it's spinning off the sepsis drug into a new biotech called BioCritica.

Exact financial details weren't disclosed, but Eli Lilly may not be footing any of the bill. Two private equity funds, Care Capital and NovaQuest Capital, are investing in BioCritica. In exchange for giving up U.S. rights to Xigris, Eli Lilly gets a stake in BioCritica. The pharma will presumably still make some money off an agreement to supply the drug to BioCritica.

Lilly isn't the first drugmaker to chuck a nonperforming asset. Biogen Idec (Nasdaq: BIIB  ) sold off Zevalin to Cell Therapeutics (Nasdaq: CTICD  ) , which eventually made its hands to Spectrum Pharmaceuticals (Nasdaq: SPPI  ) . Pfizer (NYSE: PFE  ) spun out Esperion Therapeutics after buying the biotech and realizing the assets probably weren't worth the $1.3 billion price tag.

In this case, it looks like Lilly and its investors are trying to set up BioCritica as a specialty pharma. The biotech has the option to acquire several critical-care compounds that Lilly is currently developing in the lab. And it could potentially acquire the rights to Xigris outside the U.S. at a later date.

It's not immediately clear how the spinoff benefits Lilly. Perhaps it's just a way to add value to Xigris before eventually getting BioCritica acquired. Biotech IPOs aren't a great option right now, so Lilly isn't likely to be able to sell its shares in the company anytime soon. The initiators got the state of Indiana involved through the Indiana Economic Development Corporation, so perhaps there were tax breaks or other incentives for having the drug as part of a smaller company.

Whatever the reason, investors certainly won't miss Xigris, a drug once heralded as a potential blockbuster. Sometimes you just have to cut your losses. If private equity is willing to help, all the better.

Are you a dividend investor? The Motley Fool analysts offer up 13 high-yielding stocks you can buy today.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 24, 2011, at 11:34 PM, DannyHaszard wrote:

    Spin-offs are still a *chip off the ole blockbuster*

    Eli Lilly still needs to resolve settlement issues with it's Zyprexa 'original' formula many clients still have not been paid compensation.-Daniel Haszard

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1499052, ~/Articles/ArticleHandler.aspx, 12/19/2014 10:18:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement